Roche: Xofluza approved for new patients
(CercleFinance.com) - Roche announces that the US Food and Drug Administration (FDA) has approved its Xofluza (baloxavir marboxil) in people of 12 years and older, who are at high risk of developing complications related to influenza.
The Swiss health group specifies that this category includes people suffering from diseases such as asthma, chronic lung diseases, heart disease, morbid obesity, as well as adults aged 65 or over.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Swiss health group specifies that this category includes people suffering from diseases such as asthma, chronic lung diseases, heart disease, morbid obesity, as well as adults aged 65 or over.
Copyright (c) 2019 CercleFinance.com. All rights reserved.